Progress and prospects: prospects of repeated pulmonary administration of viral vectors

Gene Ther. 2009 Sep;16(9):1059-65. doi: 10.1038/gt.2009.87. Epub 2009 Jul 30.

Abstract

Pulmonary gene therapy may ultimately cure diseases such as cystic fibrosis, alpha1-antitrypsin deficiency, lung cancer and pulmonary hypertension. Efficient expression of delivered genes in target cell types is essential for the achievement of this goal. To this end, re-administration of viral vectors may be required (1) to increase the percentage of transduced airway epithelial cells, (2) to direct gene transfer to individual lobes during successive delivery sessions or (3) to boost attenuated expression over time. Immune responses to viral proteins or viral-encoded proteins are the greatest barrier to repeated vector administration.

Publication types

  • Review

MeSH terms

  • Adaptive Immunity
  • Gene Transfer Techniques / trends*
  • Genetic Therapy / methods
  • Genetic Therapy / trends*
  • Genetic Vectors / administration & dosage*
  • Genetic Vectors / immunology
  • Humans
  • Immunity, Innate
  • Lung Diseases / therapy*
  • Viruses / genetics*
  • Viruses / immunology